Genentech VHL Inhibitor Compounds for Anemia and Cancer Treatment
Summary
The European Patent Office published patent application EP4244218A1 filed by Genentech, Inc. covering 1-(2-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)acetyl)-4-hydroxy-N-(benzyl)pyrrolidine-2-carboxamide derivatives as VHL inhibitors for the treatment of anemia and cancer. The application, published April 15, 2026, designates 31 European states including Germany, France, the United Kingdom, Italy, and Spain. IPC classifications span C07D 403/06 and C07D 417/14, with therapeutic indications covering A61P 7/06 (anemia), A61P 9/00 and A61P 9/10 (cardiovascular conditions), and A61P 35/00 (cancer).
“1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXY-N-(BENZYL)PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA AND CANCER”
About this source
GovPing monitors EPO Patent Bulletin - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 24 changes logged to date.
What changed
The European Patent Office published patent application EP4244218A1 for Genentech covering novel VHL (von Hippel-Lindau) inhibitor compounds. The chemical compounds are 1-(2-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)acetyl)-4-hydroxy-N-(benzyl)pyrrolidine-2-carboxamide derivatives specifically formulated for treating anemia and cancer. The application designates all 31 EPC contracting states.
Pharmaceutical and biotechnology companies developing treatments targeting VHL pathways or related hypoxia-inducible factor (HIF) mechanisms should review this publication to assess potential freedom-to-operate considerations or competitive landscape implications. The designated states cover major European pharmaceutical markets including Germany, France, the United Kingdom, Italy, Spain, the Netherlands, Belgium, Sweden, Austria, and Poland.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXY-N-(BENZYL)PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA AND CANCER
Publication EP4244218A1 Kind: A1 Apr 15, 2026
Applicants
Genentech, Inc.
Inventors
FUHRMANN, Jakob, WU, Hao, FAIRBROTHER, Wayne, J.
IPC Classifications
C07D 403/06 20060101AFI20220520BHEP C07D 417/14 20060101ALI20220520BHEP A61P 7/06 20060101ALI20220520BHEP A61P 9/00 20060101ALI20220520BHEP A61P 9/10 20060101ALI20220520BHEP A61P 35/00 20060101ALI20220520BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.